1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to compare progression-free survival in patients treated with
sorafenib and gemcitabine/capecitabine versus patients treated with placebo and
gemcitabine/capecitabine for locally advanced or metastatic breast cancer that has progressed
during or following treatment with a bevacizumab-containing regimen.